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GAVIN: Gene-Aware Variant INterpretation
for medical sequencing
K. Joeri van der Velde1,2, Eddy N. de Boer2, Cleo C. van Diemen2, Birgit Sikkema-Raddatz2, Kristin M. Abbott2,
Alain Knopperts2, Lude Franke2, Rolf H. Sijmons2, Tom J. de Koning2, Cisca Wijmenga2, Richard J. Sinke2
and Morris A. Swertz1,2*
Abstract
We present Gene-Aware Variant INterpretation (GAVIN), a new method that accurately classifies variants for clinical
diagnostic purposes. Classifications are based on gene-specific calibrations of allele frequencies from the ExAC
database, likely variant impact using SnpEff, and estimated deleteriousness based on CADD scores for >3000 genes.
In a benchmark on 18 clinical gene sets, we achieve a sensitivity of 91.4% and a specificity of 76.9%. This accuracy is
unmatched by 12 other tools. We provide GAVIN as an online MOLGENIS service to annotate VCF files and as an
open source executable for use in bioinformatic pipelines. It can be found at http://molgenis.org/gavin.
Keywords: Clinical next-generation sequencing, Variant classification, Automated protocol, Gene-specific calibration,
Allele frequency, Protein impact, Pathogenicity prediction
Background
Only a few years ago, the high costs and technological
challenges of whole exome and whole-genome sequen-
cing (WGS) were limiting their application. Today, the
practice of human genome sequencing has become
routine even within the healthcare sector. This is leading
to new and daunting challenges for clinical and labora-
tory geneticists [1]. Interpreting the thousands of varia-
tions observed in DNA and determining which are
pathogenic and which are benign is still difficult and
time-consuming, even when variants are prioritized by
state-of-the-art in silico prediction tools and heuristic
filters [2]. Using the current, largely manual, variant
classification protocols, it is not feasible to assess the
thousands of genomes per year now produced in a single
hospital. It is the challenge of variant assessment which
now impedes the effective uptake of next-generation
sequencing (NGS) into routine medical practice.
The recently introduced CADD [3] scores are a prom-
ising alternative [4]. These are calculated on the output
of multiple in silico tools in combination with other
genomic features. They trained a computer model on
variants that have either been under long-term selective
evolutionary pressure or none at all. The result was an
estimation of deleteriousness for variants in the human
genome, whether already observed or not. It has been
shown to be a strong and versatile predictor for patho-
genicity [3] with applications and popular uptake in
many areas of genome research. Variant interpretation
in a diagnostic setting may also benefit from this
method. However, successful uptake requires a transla-
tional effort because CADD scores are intended to rank
variants, whereas NGS diagnostics requires a discrete
classification for each variant. For example, SIFT [5]
probabilities are used to partition “tolerated” (probability
>0.05) from “damaging” variants (probability < =0.05).
CADD scores may be used to define such a binary
classifier, but using a single, arbitrary cutoff value is not
recommended by the CADD authors [6]. Moreover,
clinicians and laboratories cannot rely on a single
threshold approach because it has been shown that indi-
vidual genes differ in their cutoff thresholds for what
should be considered the optimal boundary between
pathogenic or benign [4]. This issue has been partly
addressed by mutation significance cutoff (MSC) [7],
which provides gene-based CADD cutoff values to re-
move inconsequential variants safely from sequencing
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data. While MSC aims to quickly and reliably reduce the
number of benign variants left to interpret, it was not
developed to detect/classify pathogenic variants.
The challenge is thus to find robust algorithms that
classify both pathogenic and benign variants accurately
and that fit into existing best practice, diagnostic filter-
ing protocols [8]. Implementing such tools is not trivial
because genes have different levels of tolerance to vari-
ous classes of variants that may be considered harmful
[9]. In addition, the pathogenicity estimates for benign
variants are intrinsically lower because these are more
common and of less severe consequence on protein
transcription. Comparing the prediction score distribu-
tions of pathogenic variants with those of typical benign
variants is therefore biased and questionable. Using such
an approach means it will be unclear how well a pre-
dictor truly performs if a benign variant shares the same
allele frequency and consequence with known patho-
genic variants. Here, we present Gene-Aware Variant
Interpretation (GAVIN), a new method that addresses
these issues by gene-specific calibrations on closely
matched sets of variants. GAVIN delivers accurate and




GAVIN classifies variants as benign, pathogenic, or a
variant of uncertain significance (VUS). It considers
ExAC [9] minor allele frequency, SnpEff [10] impact,
and CADD score using gene-specific thresholds. For
each gene, we ascertained ExAC allele frequencies and
effect impact distributions of variants described in
ClinVar (November 2015 release) [11] as pathogenic or
likely pathogenic. From the same genes, we selected
ExAC variants that were not present in ClinVar as a be-
nign reference set. We stratified this benign set to match
the pathogenic set with respect to the effect impact dis-
tribution and minor allele frequencies (MAFs). Using
these comparable variant sets we calculated gene-
specific mean values for CADD scores (across all genes,
the pathogenic mean of means was 28.44 and that of be-
nign was 23.08) and MAFs, as well as 95th percentile
sensitivity/specificity CADD thresholds for both benign
and pathogenic variants. Of 3237 genes that underwent
the calibration process, we found 2525 informative gene
calibrations, i.e. thresholds for CADD, effect impact,
pathogenic 95th percentile MAFs, or a combination
thereof (see Additional file 1: Table S1). We used fixed
genome-wide classification thresholds as a fallback strat-
egy based on CADD scores <15 for benign, >15 for
pathogenic, and on a MAF threshold of 0.00426, which
was the mean of all gene-specific pathogenic 95th
percentile MAFs. This allowed classification when
insufficient variant training data were available to allow
for gene-specific calibrations or when the gene-specific
rules failed to classify a variant. Based on the gene
calibrations we then implemented GAVIN, which can be
used online or via commandline (see http://molgen-
is.org/gavin) to perform variant classification.
Performance benchmark
To test the robustness of GAVIN, we evaluated its per-
formance using six benchmark variant classification sets
from VariBench [12], MutationTaster2 [13], ClinVar
(only recently added variants that were not used for
calibrating GAVIN), and a high-quality variant classifica-
tion list from the University Medical Center Groningen
(UMCG) genome diagnostics laboratory. These sets and
the origins of their variants and classifications are de-
scribed in Table 1. The combined set comprises 25,765
variants (17,063 benign, 8702 pathogenic). All variants
were annotated by SnpEff, ExAC, and CADD prior to
classification by GAVIN. To assess the clinical relevance
of our method, we stratified the combined set into clin-
ically relevant variant subsets based on organ-system
specific genes. We formed 18 subset panels such as
Cardiovascular, Dermatologic, and Oncologic based on
the gene-associated physical manifestation categories
from Clinical Genomics Database [14]. A total of 11,679
out of 25,765 variants were not linked to clinically char-
acterized genes and formed a separate panel (see Table 2
for an overview, which includes the number of patho-
genic variants in each panel). In addition, we assessed
the performance of GAVIN in compared to 12 common
in silico tools for pathogenicity prediction: MSC (using
two different settings), CADD (using three different
thresholds), SIFT [5], PolyPhen2 [15], PROVEAN [16],
Condel [17], PON-P2 [18], PredictSNP2 [19], FATHMM-
MKL [20], GWAVA [21], FunSeq [22], and DANN [23].
Across all test sets, GAVIN achieved a median sen-
sitivity of 91.4% and a median specificity of 76.9%.
Other tools with >90% sensitivity were CADD (93.6%
at threshold 15, with specificity 57.1%, and 90.4% at
threshold 20, with specificity 68.8%) and MSC (97.1%,
specificity 25.7%). The only tool with a higher specifi-
city was CADD at threshold 25 (85.3%, sensitivity
71.5%). See Table 3 for an overview of tool perform-
ance or Fig. 1 for more detail. In all the clinical gene
sets GAVIN scored >89.7% sensitivity, including >92%
for Cardiovascular, Biochemical, Obstetric, Neurologic,
Hematologic, Endocrine, and Dermatologic genes. The
non-clinical genes scored 71.3%. The specificity in
clinical subsets ranged from 70.3% for Endocrine to
84.2% for Dental. Non-clinical gene variants were
predicted at 70.6% specificity. See Additional file 2:
Table S2 for detailed results.
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Added value of gene-specific calibration
We then investigated the added value of using gene-
specific thresholds on classification performance relative
to using genome-wide thresholds. We bootstrapped the
performance on 10,000 random samples of 100 benign
and 100 pathogenic variants. These variants were drawn
from the three groups of genes described in “Methods”:
(1) genes for which CADD was significantly predictive
for pathogenicity (n = 681); (2) genes where CADD was
not significantly predictive (n = 732); and (3) genes with
scarce variant data available for calibration (n = 774). For
each of these sets we compared the use of gene-specific
CADD and MAF classification thresholds with that of
genome-wide filtering rules.
We observed the highest accuracy on genes for which
CADD had significant predictive value and for the gene-
specific classification method (median accuracy = 87.5%);
this was significantly higher than using the genome-wide
method for these same genes (median accuracy = 84.5%,
Mann–Whitney U test p value <2.2e-16). For genes for
which CADD had less predictive value, we found a lower
overall performance, but still reached a significantly
better result using the gene-specific approach (median
Table 1 Variant and classification origins of the benchmark datasets used
Dataset Benign variants (n) Pathogenic variants (n) Origin
VariBench tolerance DS7, training set 11,347 6143 PhenCode database, IDbases, and 18 individual LSDBs
VariBench tolerance DS7, test set 1377 510 PhenCode database, IDbases, and 18 individual LSDBs
MutationTaster2 benchmark set 1194 161 HGMD Professional and 1000 Genomes
ClinVar (additions of Nov 2015 to Feb 2016) 1668 1688 Submissions by clinical molecular geneticists, expert
panels, diagnostic laboratories, and companies
UMCG, variants exported from clinical
diagnostic interpretation software
1176 174 Clinical diagnostic classifications of variants in cardiology,
dermatology, epilepsy, dystonia, and preconception
screening
UMCG, germline variants for familial cancer
cases
301 26 Hereditary cancer variant classifications by an MD
following ACMG guidelines
Total 17,063 8702 25,765
















Biochemical 354 2538 1933
Cardiovascular 446 4360 2408
Craniofacial 387 1861 1106
Dental 80 783 518
Dermatologic 345 2749 1662
Endocrine 240 1801 1340
Gastrointestinal 338 2351 1620
Genitourinary 149 1026 753
Hematologic 267 2571 1914
Musculoskeletal 676 4935 2864
Neurologic 1012 6363 4055
Obstetric 34 223 140
Oncologic 203 2157 1207
Ophthalmologic 479 3649 2406
Pulmonary 90 717 485
Renal 302 2143 1459
NotInCGD 5806 11,679 122
The categories are defined by Clinical Genomics Database and are associated
to clinically relevant genes. Variants were allocated to the manifestation
categories based on their gene and were placed in multiple categories if a
gene was associated to multiple manifestations
Table 3 Performance overview of all tested tools
Tool Median sensitivity (%) Median specificity (%)
CADD (thr. 15) 93.6 57.1
CADD (thr. 20) 90.4 68.8
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accuracy = 84.5% versus genome-wide 82.5%, p value
<2.2e-16). Lastly, the worst performance was seen for
variants in genes with scarce training data available. The
gene-specific performance, however, was still significantly
better than using genome-wide thresholds (median
accuracy = 82.5% and 80.5%, respectively, p value =
2.2e-16). See Fig. 2.
Discussion
We have developed GAVIN, a method for automated
variant classification using gene-specific calibration of
classification thresholds for benign and pathogenic
variants.
Our results show that GAVIN is a powerful classifier
with consistently high performance in clinically relevant
genes. The robustness of our method arises from a
calibration strategy that first corrects for calibration bias
between benign and pathogenic variants, in terms of con-
sequence and rarity, before calculating the classification
thresholds. A comprehensive benchmark demonstrates a
unique combination of high sensitivity (>90%) and high
specificity (>70%) for variants in genes related to different
organ systems. This is a significant improvement over
existing tools that tend to achieve either a high sensitivity
(MSC, CADD at lower thresholds) or a high specificity
(PredictSNP2, CADD at higher thresholds). A high sensi-
tivity is crucial for clinical interpretation because patho-
genic variants should not be falsely discarded. In addition,
having a higher specificity means that the results will be
far less “polluted” with false positives and thus less risk
of patients being given a wrong molecular diagnosis.
GAVIN decreases false positives by 10–20% compared
to using CADD for the same purpose, thereby reducing
interpretation time. The difference between using a
high and low performance method can be dramatic in
practice. In a hypothetical example, GAVIN would
make downstream variant interpretation twice as effect-
ive as a low performance method, with more sensitive
detection of pathogenic variants (see Additional file 3:
Table S3).
Fig. 1 Performance of GAVIN and other tools across different clinical gene sets. Prediction quality is measured as sensitivity and specificity, i.e. the
fraction of pathogenic variants correctly identified and the fraction of misclassifications/non-classifications while doing so
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Even though an optimal combination of sensitivity and
specificity may be favorable in general terms, there may
still be a need for tools that perform differently. The
MSC gene-specific thresholds based on HGMD [24] at
99% confidence interval show a very high sensitivity
(97.1%), but at the expense of a very low specificity
(25.7%). Such low specificity thresholds will pick up al-
most all the pathogenic variants with scores exceeding
gene thresholds. This allows safe removal (<3% error) of
benign variants that fall below these thresholds, which
was their authors’ aim. However, this tool cannot detect
pathogenic variants due to its low specificity. Other
tools, such as PON-P2, may show a relatively low per-
formance, but not necessarily because of true errors.
Such tools may simply be very “picky” and only return a
classification when the verdict carries high confidence. If
we ignore the variants that PON-P2 did not classify
(52% of total benchmark variants) and only consider
how many of the variants that it did classify were cor-
rect, we find a positive predictive value of 96% and a
negative predictive value of 94%. Thus, while this tool
might not be useful for exome screening because too
many pathogenic variants would be lost, it can still be
an excellent choice for further investigation of interest-
ing variants. We would therefore emphasize that appro-
priate tools should be selected depending on the
question or analysis protocol used and by taking their
strengths and weaknesses into account.
Not surprisingly, we could confirm that the use of
gene-specific thresholds instead of genome-wide thresh-
olds led to a consistent and significant improvement of
classification performance. This shows the added value
of our strategy. Overall performance was slightly lower
in genes for which CADD has limited predictive value
and even lower in genes with few “gold standard” patho-
genicity data available. Evaluating variants in uncharac-
terized genes is rare in clinical diagnostics, although it
may occur when exome sequencing is aimed at solving
complex phenotypes or undiagnosed cases. Nevertheless,
GAVIN is likely to improve continuously in an increas-
ing number of genes, propelled by the speed at which
pathogenic variants are now being reported. The results of
this paper are based on the ClinVar release of November
2015 and comprise 2525 informative gene calibrations, i.e.
thresholds for CADD, impact, MAF, or a combination
thereof. When we calibrate on the September 2016
ClinVar release, we obtain more informative gene calibra-
tions (2770) with stable gene CADD thresholds (mean
pathogenic difference of 0.1%, mean benign difference of
1.1%) and a slight drop in pathogenic MAF (0.00426 to
0.00346). Using these newer calibrations, the benchmark
performance of GAVIN increases to 91.7% sensitivity (up
from 91.4%) and 78.2% specificity (up from 76.9%). If this
trend continues and (2770-2525)/10 = 24.5 genes per
month are added, we estimate that calibrating all disease
genes in CGD (3316 per Sept. 2016) will take another
(3316-2770)/24.5/12 = 1.86 ≈ 2 years.
With GAVIN, we were also able to demonstrate the re-
sidual power of CADD scores as a predictor for pathogen-
icity on a gene-by-gene basis, revealing that the scores are
informative for many genes (these results can be accessed
at http://molgenis.org/gavin). There are several possible
explanations for potential non-informativity of CADD
scores. It may have bias towards the in silico tools and
sources it was trained on, limiting their predictiveness for
certain genomic regions or disease mechanisms [25].
Fig. 2 Comparison of gene-specific classification thresholds with genome-wide fixed thresholds in three groups of genes: 737 genes for which
CADD is predictive, 684 genes for which CADD is less predictive, and 766 genes with scarce training data. For each group, 10,000 sets of 100
benign and 100 pathogenic variants were randomly sampled and tested from the full set of 25,765 variants and accuracy was calculated for
gene-specific and genome-wide CADD and MAF thresholds
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Furthermore, calibration of pathogenic variants could be
difficult in genes with high damage tolerance, i.e. having
many missense or loss-of-function mutations [26]. In
addition, calibration may be impaired by false input
signals, such as an incorrect pathogenic classification in
ClinVar or inclusion of disease cohorts in large databases
such as ExAC could misrepresent allele frequencies [27].
Lastly, pathogenic variants could have a low penetrance or
their effect mitigated by genetic modifiers, causing high
deleteriousness to be tolerated in the general population
against expectations [28].
The field of clinical genomics is now moving towards
interpretation of non-coding disease variants (NCVs)
identified by WGS [29]. A number of recently intro-
duced metrics, including EIGEN [30], FATHMM-MKL,
DeepSEA [31], and GWAVA, specialize in predicting the
functional effects of non-coding sequence variation.
When a pathogenic NCV reference set of reasonable
quantity becomes available, a calibration strategy as
described here will be essential to be able to use these
metrics effectively in whole-genome diagnostics.
Conclusions
GAVIN provides an automated decision-support proto-
col for classifying variants, which will continue to im-
prove in scope and precision as more data are publicly
shared by genome diagnostic laboratories. Our ap-
proach bridges the gap between estimates of genome-
wide and population-wide variant pathogenicity and
contributes to their practical usefulness for interpreting
clinical variants in specific patient populations. Data-
bases such as ClinVar contain a wealth of implicit rules
now used manually by human experts to classify vari-
ants. Rules on minor allele frequencies, estimated effect
impact, and CADD scores are deduced and employed
by GAVIN to classify variants that have not been seen
before.
We envision GAVIN accelerating NGS diagnostics
and becoming particularly beneficial as a powerful
(clinical) exome screening tool. It can be used to
quickly and effectively detect over 90% of pathogenic
variants in a given dataset and to present these results
with an unprecedented small number of false positives.
It may especially serve laboratories that lack the re-
sources necessary to perform reliable and large-scale
manual variant interpretation for their patients and
spur the development of more advanced gene-specific
classification methods. We provide GAVIN as an online
MOLGENIS [32] web service to browse gene calibra-
tion results and annotate VCF files and as a command-
line executable including open source code for use in
bioinformatic pipelines. GAVIN can be found at http://
molgenis.org/gavin.
Methods
Calibration of gene-specific thresholds
We downloaded ClinVar (variant_summary.txt.gz from
ClinVar FTP, last modified date: 05/11/15) and selected
GRCh37 variants that contained the word “pathogenic” in
their clinical significance. These variants were matched
against the ClinVar VCF release (clinvar.vcf.gz, last modi-
fied date: 01/10/15) using RS (Reference SNP) identifiers
in order to resolve missing indel notations. On the result-
ing VCF, we ran SnpEff version 4.1 L with these settings:
hg19 -noStats -noLog -lof -canon -ud 0. As a benign refer-
ence set, we selected variants from ExAC (release 0.3, all
sites) from the same genic regions with +/– 100 bases of
padding on each side to capture more variants residing on
the same exon. We first determined the thresholds for
gene-specific pathogenic allele frequency by taking the
ExAC allele frequency of each pathogenic variant or
assigning zero if the variant was not present in ExAC, and
calculating the 95th percentile value per gene using the R7
method from Apache Commons Math version 3.5. We
filtered the set of benign variants with this threshold to
retain only variants that were rare enough to fall into the
pathogenic frequency range.
Following this step, the pathogenic impact distribution
was calculated as the relative proportion of the general-
ized effect impact categories, as annotated by SnpEff on
the pathogenic variants. The same calculation was
performed on the benign variants uniquely present in
ExaC. To facilitate this, we annotated ExAC with SnpEff
(4.1 L, same settings as above) to get the same impact,
transcript, and gene nomenclature as our ClinVar set.
Overlapping genes were not an issue because SnpEff
variant annotations include the gene symbol to which an
estimated impact is applicable and subsequently only
those matching impacts were considered. The benign
variants were subsequently downsized to match the
impact distribution of the pathogenic variants.
For instance, in the case of 407 pathogenic MYH7 var-
iants, we found a pathogenic allele frequency threshold
of 4.942e-5, and an impact distribution of 5.41% HIGH,
77.4% MODERATE, 17.2% LOW, and 0% MODIFIER.
We defined a matching set of benign variants by retriev-
ing 1799 MYH7 variants from ExAC (impact distribu-
tion: 2% HIGH, 23.59% MODERATE, 32.59% LOW,
41.82% MODIFIER), from which we excluded known
ClinVar pathogenic variants (n = 99), variants above the
AF threshold (n = 246), and removed interspersed vari-
ants using a non-random “step over” algorithm until the
impact distribution was equalized (n = 960). We thus
reached an equalized benign set of 494 variants, having
an impact distribution of 5.47% HIGH, 77.33% MODER-
ATE, 17.21% LOW, and 0% MODIFIER).
We then obtained the CADD scores for all variants
and tested whether there was a significant difference in
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scores between the sets of pathogenic and benign vari-
ants for each gene, using a Mann–Whitney U test. Per
gene we determined the mean CADD score for each
group and also the 95th percentile sensitivity threshold
(detection of most pathogenic variants while accepting
false positives) and 95th percentile specificity threshold
(detection of most benign variants while accepting false
negatives) using the Percentile R7 function. All statistics
were done with Apache Commons Math version 3.5. This
calibration process was repeated for 3237 genes, resulting
in 2525 genes for which we learned classification rules in-
volving pathogenic variant MAF, effect impact distribu-
tion, CADD score thresholds, or a combination thereof.
On average, CADD scores were informative of patho-
genicity. The mean benign variant CADD score across
all genes was 23.08, while the mean pathogenic variant
CADD score was 28.44, a mean difference of 5.36 (σ =
4.80). Of 3237 genes that underwent the calibration
process, we found 681 “CADD predictive” genes that
had a significantly higher CADD score for pathogenic
variants than for benign variants (Mann–Whitney U
test, p value <0.05). Interestingly, we also found 732
“CADD less predictive” genes, for which there was no
proven difference between benign and pathogenic vari-
ants (p value >0.05 despite having ≥5 pathogenic and ≥5
benign variants in the gene). For 774 genes, there were
few calibration data available (<5 pathogenic or <5 be-
nign variants), resulting in no significant difference (p
value >0.05) between CADD scores of pathogenic and
benign variants. We also found 159 genes for which ef-
fect impact alone was predictive, meaning that a certain
impact category was unique for pathogenic variants
compared to benign variants. For instance, if we observe
HIGH impact pathogenic variants (frame shift, stopgain,
etc.) for a given gene, whereas benign variants only reach
MODERATE impact (missense, inframe insertion, etc.),
we use this criterion as a direct classifier. No further
CADD calibration was performed on these genes. In
summary, the total set of 3237 genes comprises 681
“CADD predictive” genes + 732 “CADD less predictive”
genes + 774 “little calibration data” genes + 159 “impact
predictive” + 178 genes with only pathogenic MAF cali-
brated + 712 genes without calibration due to less than 2
ClinVar or ExAC variants available + 1 artifact where
population CADD was greater than pathogenic CADD.
See Additional file 1: Table S1 for details.
Variant sets for benchmarking
We obtained six variant sets that had been classified by
human experts. These datasets were used to benchmark
the in silico variant pathogenicity prediction tools men-
tioned in this paper. Variants from the original sets may
sometimes be lost due to conversion of cDNA/HGVS
notation to VCF.
The VariBench protein tolerance dataset 7 (http://struc-
ture.bmc.lu.se/VariBench/) contains disease-causing mis-
sense variations from the PhenCode [33] database, IDbases
[34], and 18 individual LSDBs [12]. The training set we used
contained 17,490 variants, of which 11,347 were benign and
6143 pathogenic. The test set contained 1887 variants, of
which 1377 were benign and 510 pathogenic. We used both
the training set and test set as benchmarking sets.
The MutationTaster2 [13] test set contains known
disease mutations from HGMD [24] Professional and
putatively harmless polymorphisms from 1000 Genomes.
It is available at http://www.mutationtaster.org/info/
Comparison_20130328_with_results_ClinVar.html. This
set contains 1355 variants, of which 1194 are benign and
161 pathogenic.
We selected 1688 pathogenic variants from ClinVar
that were added between November 2015 and February
2016 as an additional benchmarking set, since our
method was based on the November 2015 release of
ClinVar. We supplemented this set with a random selec-
tion of 1668 benign variants from ClinVar, yielding a
total of 3356 variants.
We obtained an in-house list of 2359 variants that had
been classified by molecular and clinical geneticists at
the University Medical Center Groningen. These vari-
ants belong to patients seen in the context of various
disorders: cardiomyopathies, epilepsy, dystonia, precon-
ception carrier screening, and dermatology. Variants
were analyzed according to Dutch medical center guide-
lines [35] for variant interpretation, using Cartagenia
Bench Lab™ (Agilent Technologies) and Alamut® soft-
ware (Interactive Biosoftware) by evaluating in-house
databases, known population databases (1000G [36],
ExAC, ESP6500 at http://evs.gs.washington.edu/EVS/,
GoNL [37]), functional effect, and literature searches.
Any ClinVar variants included in the November 2015
release were removed from this set to prevent circular
reasoning, resulting in a total of 1512 variants, with 1176
benign/likely benign (merged as Benign), 162 VUS, and
174 pathogenic/likely pathogenic (merged as Pathogenic).
From the UMCG diagnostics laboratory we also
obtained a list of 607 variants seen in the context of
familial cancers. These were interpreted by a medical
doctor according to ACMG guidelines [8]. We removed
any ClinVar variants (November 2015 release), resulting
in 395 variants, with 301 benign/likely benign (merged
as Benign), 68 VUS, and 26 likely pathogenic/pathogenic
(merged as Pathogenic).
Variant data processing and preparation
We used Ensembl VEP (http://grch37.ensembl.org/Homo_-
sapiens/Tools/VEP/) to convert cDNA/HGVS notations to
VCF format. Newly introduced N-notated reference bases
were replaced with the appropriate GRCh37 base, and
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alleles were trimmed where needed (e.g. “TA/TTA” to “T/
TT”). We annotated with SnpEff (version 4.2) using the
following settings: hg19 -noStats -noLog -lof -canon -ud 0.
CADD scores (version 1.3) were added by running the vari-
ants through the CADD webservice (available at http://
cadd.gs.washington.edu/score). ExAC (release 0.3) allele fre-
quencies were added with MOLGENIS annotator (release
1.16.2). We also merged all benchmarking sets into a com-
bined file with 25,995 variants (of which 25,765 classified as
benign, likely benign, likely pathogenic, or pathogenic) for
submission to various online in silico prediction tools.
Execution of in silico predictors
The combined set of 25,765 variants was classified by
the in silico variant pathogenicity predictors (MSC,
CADD, SIFT, PolyPhen2, PROVEAN, Condel, PON-P2,
PredictSNP2, FATHMM, GWAVA, FunSeq, DANN).
The output of each tool was loaded into a program that
compared the observed output to the expected classifica-
tion and which then calculated performance metrics
such as sensitivity and specificity. The tools that we eval-
uated and the web addresses used can be found in
Additional file 4: Table S4. We executed PROVEAN and
SIFT, for which the output was reduced by retaining the
following columns: “INPUT,” “PROVEAN PREDICTION
(cutoff = -2.5),” and “SIFT PREDICTION (cutoff = 0.05).”
For PONP-2, the output was left as is. The MSC thresh-
olds are configurable; we downloaded the ClinVar-based
thresholds for CADD 1.3 at 95% confidence interval,
comparable to our method, as well as HGMD-based
thresholds at 99% confidence interval, the default set-
ting. Variants below the gene-specific thresholds were
considered benign, and above the threshold pathogenic.
Following the suggestion of the CADD authors, scores
of variants below a threshold of 15 were considered
benign, above this threshold pathogenic. We also tested
CADD thresholds 20 and 25 for comparison. The output
of Condel was reduced by retaining the following
columns: “CHR,” “START,” “SYMBOL,” “REF,” “ALT,”
“MA,” “FATHMM,” “CONDEL,” “CONDEL_LABEL.”.
After running PolyPhen2, its output was reduced by retain-
ing the positional information (“chr2:220285283|CG”) and
the “prediction” column. Finally, we executed PredictSNP2,
which contains the output from multiple tools. From the
output VCF, we used the INFO fields “PSNPE,” “FATE,”
“GWAVAE,” “DANNE,” and “FUNE” for the pathogenicity
estimation outcomes according to the PredictSNP protocol
for PredictSNP2 consensus, FATHMM, GWAVA, DANN,
and FunSeq, respectively.
Stratification of variants using Clinical Genomics Database
We downloaded Clinical Genomics Database (CGD;
the.tsv.gz version on 1 June 2016 from http://research.nh-
gri.nih.gov/CGD/download/). A Java program evaluated
each variant in the full set of 25,765 variants and retrieved
their associate gene symbols as annotated by SnpEff. We
matched the gene symbols to the genes present in CGD
and retrieved the corresponding physical manifestation
categories. Variants were then written out to separate files
for each manifestation category (cardiovascular, craniofa-
cial, renal, etc.). This means a variant may be output into
multiple files if its gene was linked to multiple manifest-
ation categories. However, we did prevent variants from
being written out twice to the same file in the case of
overlapping genes in the same manifestation categories.
We output a variant into the “NotInCGD” file only if it
was not located in any gene present in CGD.
Implementation
GAVIN was implemented using Java 1.8 and MOLGENIS
[32] 1.21 (http://molgenis.org). The calibration method is
agnostic of the meaning of pathogenic or benign, resulting
in thresholds that have balanced sensitivity and specificity.
In our diagnostics practice, sensitivity is valued over specifi-
city. We therefore adjusted the CADD and MAF thresholds
to shift the balance towards sensitivity at the cost of specifi-
city. We found a setting of 5 (adjustable in source code)
achieved >90% sensitivity and this setting was used to gen-
erate final thresholds. The genome-wide classification
thresholds based on CADD scores <15 for benign and >15
for pathogenic matched this high sensitivity. The full table
of gene-specific thresholds used can be found at http://
www.molgenis.org/gavin (for latest release) or Additional
file 1: Table S1. They can be used to guide manual variant
interpretation or be re-used in other tools. Source code
with tool implementation details can be found at https://
github.com/molgenis/gavin. All benchmarking, bootstrap-
ping, and plotting tools can be found in this repository, as
well as all data processing and calibration programs.
Binary classification metrics
Prediction tools may classify variants as benign or patho-
genic, but may also fail to reach a classification or classify
a variant as VUS. Because of these three outcome states,
binary classification metrics must be used with caution.
We define sensitivity as the number of detected patho-
genic variants (true positives) over the total number of
pathogenic variants, which includes true positives, false
negatives (pathogenic variants misclassified as benign),
and pathogenic variants that were otherwise “missed,” i.e.
classified as VUS or not classified at all. Therefore, Sensi-
tivity = TruePositive/(TruePositive + FalseNegative +Mis-
sedPositive). We applied the same definition for specificity
and define it as: Specificity = TrueNegative/(TrueNegative
+ FalsePositive +MissedNegative). Following this line, ac-
curacy is then defined as (TruePositive + TrueNegative)/
(TruePositive + TrueNegative + FalsePositive + FalseNega-
tive +MissedPositive +MissedNegative).
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Additional files
Additional file 1: Table S1. GAVIN gene-specific thresholds used in the
benchmark. This table can be used to look up thresholds of individual
genes and allow variant interpretation by following classification rules as
indicated by the column names and provided explanation. (XLSX 198 kb)
Additional file 2: Table S2. Detailed overview of all benchmark results.
Each combination of tool and dataset is listed. We provide the raw
counts of true positives (TP), true negatives (TN), false positives (FP), and
false negatives (FN), as well as of pathogenic and benign variants that
were “missed,” i.e. not correctly identified as such. From these numbers,
we calculated the sensitivity and specificity. (XLSX 58 kb)
Additional file 3: Table S3. Estimate of the practical impact in clinical
diagnostics of using methods of different sensitivity and specificity on a
dataset with 100 benign and 10 pathogenic variants. (XLSX 50 kb)
Additional file 4: Table S4. The tools used to evaluate our benchmark
variant set and the web addresses used through which they were
accessed. (XLSX 51 kb)
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